Cidara Therapeutics Inc (CDTX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|2013||Chairman of the Board|
|62||2014||President, Chief Executive Officer, Director|
|45||2018||Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, General Counsel, Secretary|
|63||2014||Chief Development Officer|
|46||2014||Chief Commercial Officer|
- BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln
- BRIEF-Cidara Therapeutics Files For Stock Shelf Of Up To $10 Mln
- BRIEF-Cidara Reports Q1 Loss Per Share $0.80
- BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin
- BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin